Back to the episode

Matrx Mix Podcast

Recent Breakthroughs in Huntington's Disease: Moving Beyond Symptom Management

By Mark, Sarah

Recent Breakthroughs in Huntington's Disease: Moving Beyond Symptom Management
# Recent Breakthroughs in Huntington's Disease: Moving Beyond Symptom Management Historically, Huntington's disease has been a devastating diagnosis. As a fatal, inherited neurodegenerative disorder, its treatments were long confined to simply managing symptoms rather than altering the biological course of the illness. However, the medical landscape experienced historic, paradigm-shifting advancements throughout 2024 and 2025. For the first time since the genetic cause of the disease was discovered in 1993, scientists and pharmaceutical companies are introducing therapies that actively slow disease progression. This shift from symptom management to root-cause intervention is offering an unprecedented wave of hope for families affected by Huntington's. ## The Gene Therapy Game-Changer: AMT-130 In late 2025, a landmark development emerged from uniQure with preliminary success in its Phase 1 and 2 clinical trials for a gene therapy known as AMT-130. Unlike a daily pill, AMT-130 is designed as an intensive, one-time treatment requiring a 12-to-18-hour neurosurgical procedure. Doctors utilize an AAV vector—a harmless, modified virus—to deliver micro-RNAs directly into the brain's striatum. These micro-RNAs act as biological brakes, inhibiting the production of mHTT, the toxic mutant protein responsible for Huntington's. The trial results were remarkable. Patients receiving a high dose of AMT-130 experienced a 75 percent slowing of disease progression over 36 months, measured against an external control group using the composite Unified Huntington's Disease Rating Scale. This clinical success was backed by biological evidence: cerebrospinal fluid levels of neurofilament light protein (NfL), a key biomarker of brain cell death, dropped by an average of 8.2 percent. Armed with Breakthrough Therapy, Orphan Drug, and Regenerative Medicine Advanced Therapy designations from the FDA, AMT-130 is on a fast track to potentially becoming the world's first disease-modifying treatment for Huntington's. ## Promising Oral Medications: Votoplam and Tominersen While surgical gene therapies offer a targeted, one-time approach, the pharmaceutical industry is also making rapid progress with less invasive oral medications. A standout in this category is Votoplam (PTC518), developed by PTC Therapeutics. A daily oral pill, Votoplam works by modulating gene splicing to lower toxic Huntington protein levels. Two-year clinical trial data released in May 2025 showed that the drug slowed disease progression by up to 52 percent in Stage 2 participants.

Prefer to listen?

Huntington's Breakthroughs: The End of Symptom-Only Management?

Huntington's Breakthroughs: The End of Symptom-Only Management?

Huntington's Breakthroughs: The End of Symptom-Only Management?

--:--

0:00--:--
The momentum doesn't stop there. Roche is evaluating tominersen in patients with early or prodromal Huntington's, and a crowded field of competitors—including Skyhawk Therapeutics, Spark Therapeutics, and Alnylam Pharmaceuticals—are launching their own multi-phase trials. Concurrently, Neurocrine Biosciences has focused on advancing symptom management, successfully completing a Phase 3 trial for Valbenazine to treat chorea, the involuntary movements that heavily characterize the disease. ## CRISPR, Stem Cells, and the Future of Basic Science Behind these clinical trials is a robust foundation of basic scientific research fueling the next generation of therapies. In August 2025, scientists established a direct cause-and-effect link between faulty mitochondria and memory loss in neurodegenerative diseases like Huntington's, opening up entirely new pathways for therapeutic intervention. Beyond cellular energy, researchers are investigating advanced genetic and regenerative tools. Preclinical studies in mice have successfully utilized CRISPR gene editing to disrupt the Huntington's mutation, laying the groundwork for what could eventually become a permanent genetic cure. In human trials, scientists are even investigating intravenous dental pulp stem cell therapy as a regenerative approach to combat the neurological damage caused by the disease. ## The Ultimate Goal: "Stage Zero" Prevention The holy grail of Huntington's research is halting the disease before symptoms ever manifest. Through advanced imaging and spinal fluid analyses, medical professionals now understand that subtle changes occur in the brain up to 20 years before a clinical motor diagnosis is ever made. This profound realization has sparked a push for "Stage Zero" prevention trials. The ambitious goal is to proactively treat young individuals who carry the Huntington's gene long before they develop a single tremor or any cognitive decline, effectively ending the disease as we know it. While revolutionary treatments like AMT-130 and Votoplam still need to complete larger, peer-reviewed Phase 3 trials to secure full FDA approval, the shift from symptom management to true disease modification represents a monumental medical breakthrough. Families finally have tangible reasons for hope. To hear a deeper dive into the science behind these incredible advancements, listen to the full "Huntington's Breakthroughs" episode of the Matrx Mix Podcast.
Watch the episode highlights